ASCO Issues HER2-Negative Breast Cancer Guide

“ASCO Issues HER2-Negative Breast Cancer Guide?” By Charles Bankhead, MedPage Today.

Editorial Note: After reviewing medical literature from 1993 through May 2013, the American Society of Clinical Oncology (ASCO) developed a new set of clinical guidelines for patients with advanced HER2-negative breast cancer. The review included findings from 59 randomized clinical trials and 20 systematic . . . → Read More: ASCO Issues HER2-Negative Breast Cancer Guide

Do Clinical Trials Work?

“Do Clinical Trials Work?” The New York Times on Jul. 13, 2013.

EVERY spring, some 30,000 oncologists, medical researchers and marketers gather in an American city to showcase the latest advances in cancer treatment. But at the annual meeting of the American Society of Clinical Oncology last month, much of the buzz surrounded a study . . . → Read More: Do Clinical Trials Work?

Research Brief --

Dr. Patricia Steeg

Patricia S. Steeg, chief of the Center for Cancer Research at the National Cancer Institute, argues in Nature [2012, 485, S58a] that most people with breast cancer die as a result of metastases (spread). Clinical trials, however, are only designed to evaluate a drug’s ability to shrink established tumors rather . . . → Read More: Research Brief — “The Right Trials”

A Conversation with Dr. Patricia Steeg on Redesigning Clinical Trials to Test Therapies that Could Prevent Cancer Metastasis

“A Conversation with Dr. Patricia Steeg on Redesigning Clinical Trials to Test Therapies that Could Prevent Cancer Metastasis” National Cancer Institute Cancer Bulletin

In a perspective published May 30 in Nature, Dr. Patricia Steeg argues that the current system for clinical trials must be redesigned if there is to be a decline in breast cancer . . . → Read More: A Conversation with Dr. Patricia Steeg on Redesigning Clinical Trials to Test Therapies that Could Prevent Cancer Metastasis